Gilead Sciences

Sector: Companies & groupsHQ: UNITED STATES

EU Lobbying Profiles

Gilead Sciences

Register: EU_TRANSPARENCY_REGISTER

Declared Spend (Max)

€1,249,999

Regulatory Meetings

Life Sciences Roundtable

Met with Olivér Várhelyi (EU)

Exchange of views on developments in the pharmaceutical industry and aspects of competition law and policy enforcement in this industry sector

Met with Ulla Schwager (EU)

HIV prevention

Met with Boriša Falatar (EU)

Gilead’s long-acting HIV prevention drug: LENACAPAVIR – access in Africa

Met with Cecile Billaux (EU)

Exchange of views on issues relating to competitiveness and corporate sustainability

Met with Michael McGrath (EU)

General Exchange on the Company’s Activities

Met with Vincenzo Matano (EU)

Meeting with Spanish Women’s Coalition on Triple Negative Breast Cancer on Europe’s Beating Cancer Plan and EU policies on cancer

Met with Tove Ernst (EU)

Meeting with Spanish Women’s Coalition on Triple Negative Breast Cancer on Europe’s Beating Cancer Plan and EU policies on cancer

Met with Stella Kyriakides (EU)

Discussed Gilead’s manufacturing operations in Ireland and globally. Gilead outlined their concerns with the soon to be published EU Pharmaceutical strategy, with particular emphasis on unmet medical needs, regulatory data protection and innovation

Met with Patricia Reilly (EU)

Exchange of views on joint procurement and scientific assessment of Remdesivir

Met with Stella Kyriakides (EU)

Government Procurement

Spain – Antineoplastic agents – Suministro sucesivo del medicamento Axicabtagen Ciloleucel → GILEAD SCIENCES, S.L. — Contract awarded to GILEAD SCIENCES, S.L. by Servizo Galego de Saúde. Área Sanitaria de Vigo

Spain – Antineoplastic agents – Suministro sucesivo del medicamento Axicabtagen Ciloleucel → GILEAD SCIENCES, S.L. — Contract awarded to GILEAD SCIENCES, S.L. by Servizo Galego de Saúde. Área Sanitaria de Vigo

Executive Insider Trades

No executive insider trades reported.